Efficacy of intermittent pyrazinamide in experimental murine tuberculosis.
CFLP mice were infected intravenously with Mycobacterium tuberculosis strain H37Rv and the progress of chemotherapy was followed by counts of viable bacilli in the lung and spleen. After spleen counts had reached log10 7.0, 12 experimental groups, each containing 10 mice, were treated for 8 weeks with pyrazinamide (PZA) given in mean daily dosages of 100, 200 or 400 mg/kg/day, with the interval between the doses within each dosage group being 1, 2, 4 or 8 days. All mice were also given 25 mg isoniazid/kg daily. An increase in the mean daily dosage from 100 mg PZA/kg to 400 mg PZA/kg resulted in a decrease of spleen viable counts at the end of treatment from log10 4.2 to log10 3.8. The organ counts, averaged over the full dosage range, were little altered by spacing out the interval between doses from 1-4 days, while increasing dose size proportionately: the counts with low mean dosages tended, however, to decrease (indicating improved efficacy) while those with high mean dosages increased (P less than 0.001). Counts increased when the interval was 8 days. Spacing out the doses while keeping the dose size constant resulted in progressive loss of efficacy. These findings suggest that, if PZA is given intermittently, the size of the dose should be increased, though not quite proportionately, to maintain full efficacy. Even with such an increase in dose, however, once weekly treatment would be less effective.
Dickinson
J M
JM
Department of Bacteriology, Royal Postgraduate Medical School, London, UK.
Mitchison
D A
DA
D000818:Animals; D015169:Colony Count, Microbial; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D007538:Isoniazid / Q000627:therapeutic use; D008168:Lung / Q000382:microbiology; D051379:Mice; D008815:Mice, Inbred Strains; D011718:Pyrazinamide / Q000008:administration & dosage* / Q000627:therapeutic use; D013154:Spleen / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology; D014400:Tuberculosis, Splenic / Q000188:drug therapy* / Q000382:microbiology
D011718:Pyrazinamide; D007538:Isoniazid